SEC Form 10-K filed by Inogen Inc

4 - Inogen Inc (0001294133) (Issuer)

4 - Inogen Inc (0001294133) (Issuer)

4 - Inogen Inc (0001294133) (Issuer)

Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock. "This authorization reflects our confidence in Inogen's strategy, progress towards profitability goals, and long-term growth trajectory," said Kevin Smith, President and Chief Executive Officer. "With a strong, debt-free balance sheet, we view this program as providing additional flexibility to deploy capital to support continued investment in innovation and portfolio expansion while enhancing shareholder value." The r

Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025. Recent Highlights $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million $2.3 million adjusted EBITDA, the third consecutive quart

SC 13G/A - Inogen Inc (0001294133) (Subject)

SC 13G - Inogen Inc (0001294133) (Subject)

SC 13G/A - Inogen Inc (0001294133) (Subject)